GENESIS THERAPEUTICS
Their academia-leading research was the initial component of our expanding portfolio of AI technologies. They are combining novel deep neural networks, biophysical simulation, and massively scalable computing infrastructure to achieve industry-leading performance in a molecular generation and property prediction. The company was founded in 2019 and based in South San Francisco, California.
GENESIS THERAPEUTICS
Social Links:
Industry:
Artificial Intelligence Biotechnology Information Technology
Founded:
2019-11-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.genesistherapeutics.ai
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
56.1 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Google Universal Analytics
Similar Organizations
Dyno Therapeutics
Dyno Therapeutics is a biotechnology company that uses artificial intelligence for gene therapy.
Emedgene
Emedgene provides data-driven AI solutions for genomic diagnostics and discovery at scale.
Raze Therapeutics
Raze Therapeutics, Inc., a biotechnology company, engages in the discovery and development of oncology therapeutics.
Current Advisors List
Current Employees Featured
Founder
Investors List
T. Rowe Price
T. Rowe Price investment in Series A - Genesis Therapeutics
Jazz Venture Partners
Jazz Venture Partners investment in Series A - Genesis Therapeutics
Menlo Ventures
Menlo Ventures investment in Series A - Genesis Therapeutics
Radical Ventures
Radical Ventures investment in Series A - Genesis Therapeutics
Propagator Ventures
Propagator Ventures investment in Series A - Genesis Therapeutics
Jeffrey Rothschild
Jeffrey Rothschild investment in Series A - Genesis Therapeutics
Rock Springs Capital
Rock Springs Capital investment in Series A - Genesis Therapeutics
Ulu Ventures
Ulu Ventures investment in Series A - Genesis Therapeutics
Open Field Capital
Open Field Capital investment in Series A - Genesis Therapeutics
Felicis Ventures
Felicis Ventures investment in Series A - Genesis Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-04-28 | Genesis Therapeutics Expands Executive Team with Addition of Will McCarthy as Chief Business … |
Official Site Inspections
http://www.genesistherapeutics.ai Semrush global rank: 5.72 M Semrush visits lastest month: 1.46 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Genesis Therapeutics"
Home - Genesis Therapeutics
Sep 10, 2024 GEMS: Generative AI for Drug Discovery. GEMS synthesizes our proprietary AI + physics research into a state-of-the-art platform. Our scientists use GEMS to find drug candidates against difficult targets, demonstrating …See details»
People - Genesis Therapeutics
Aug 21, 2023 Genesis integrates biotech veterans with leading AI researchers, all driven to optimize drug discovery and create life-changing medicines. We are supported by world …See details»
Careers - Genesis Therapeutics
Genesis is full of multi-dimensional, curious, and open-minded people. Join us to be a part of a world-class team of innovators and drug hunters changing the way we find treatments for …See details»
Genesis Therapeutic - Crunchbase Company Profile
Contact Email [email protected] Phone Number +1(208) 991-4716 Genesis Therapeutics is a company that has its roots in academic research, which serves as the foundational element of its growing portfolio of AI …See details»
Genesis Therapeutics - LinkedIn
Genesis Therapeutics | 11,749 followers on LinkedIn. Unifying AI and Biotech to accelerate the discovery of new medicines | Genesis Therapeutics – headquartered in Burlingame, CA, with a fully ...See details»
Gilead and Genesis Therapeutics Announce Strategic …
Sep 10, 2024 GEMS integrates proprietary AI methods, including language models, diffusion models and physical ML simulations, to generate and optimize molecules for complex targets. …See details»
Genesis Therapeutics Company Profile 2024: Valuation, …
Genesis Therapeutics General Information Description. Developer of a computational platform designed for the discovery of small-molecule drugs. The company leverages a proprietary molecular AI technology that drives the …See details»
Genesis Therapeutics Secures $52M Series A to Further …
Dec 2, 2020 Genesis Therapeutics is a unique organization that revolves around a true collaboration between drug hunters, who have discovered and/or developed multiple FDA-approved drugs, and accomplished AI ...See details»
Gilead and Genesis Therapeutics Announce Strategic …
FOSTER CITY, Calif. & BURLINGAME, Calif., September 10, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics, Inc. announced today that the companies have …See details»
Fierce Medtech Names Genesis Therapeutics a "Fierce 15" …
BURLINGAME, Calif., March 06, 2024--Genesis Therapeutics, a company pioneering generative and predictive artificial intelligence (AI) technologies to develop breakthrough therapeutics for ...See details»
Gilead and Genesis Therapeutics Announce Strategic …
Sep 10, 2024 - Gilead and Genesis Will Leverage the GEMS AI Platform to Generate and Jointly Optimize Molecules Against Selected Targets - - Gilead Receives Exclusive Rights to Develop …See details»
Pipeline - Genesis Therapeutics
Mar 6, 2024 Best-in-class pan-mutant PIK3CA. PIK3CA is a common oncogenic driver in breast and colorectal cancers. Genesis is advancing multiple lead molecules and approaching …See details»
Genesis Therapeutics Announces Strategic Collaboration with Lilly …
May 3, 2022 Genesis Therapeutics has created the industry's most advanced molecular AI platform by combining 3D structure-aware deep neural networks, new molecular simulation …See details»
Genesis Therapeutics Announces New Equity Investment and …
Nov 13, 2024 Genesis Therapeutics is an AI-focused biotechnology company leveraging its generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space) …See details»
AI Platform - Genesis Therapeutics
Oct 31, 2023 Genesis has pioneered state-of-the-art AI methods to predict protein-ligand structures, using diffusion models to efficiently sample the critical 3D structures for protein …See details»
Genesis Therapeutics Announces New Equity Investment and
Nov 13, 2024 BURLINGAME, Calif.--(BUSINESS WIRE)--Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for …See details»
Gilead and Genesis Therapeutics Announce Strategic …
Sep 10, 2024 [email protected]. Gilead Info Meaghan Smith, Media [email protected]. Jacquie Ross, Investors [email protected].See details»
How to Create Value Systematically with Gen AI - Harvard Business …
16 hours ago The difference between incremental and transformative gen AI lies not in technical sophistication or strategic vision, but in a shared understanding of what drives performance for …See details»
News - Genesis Therapeutics
Sep 10, 2024 Gilead and Genesis will leverage the GEMS AI platform to generate and jointly optimize molecules against selected targets. Genesis will receive an upfront cash payment of …See details»
Genesis Therapeutics Announces New Equity Investment and …
BURLINGAME, Calif., November 13, 2024--Genesis Therapeutics announces new equity investment and collaboration with NVIDIA to optimize key computational methods for AI …See details»